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Breast metastasis from rectal carcinoma: A case report 
and review of the literature
Case Report
Case presentation
We report a case of  breast metastasis from rectal carcinoma 
in a middle-age woman who had been diagnosed and 
treated for the primary rectal cancer 16 months prior to the 
noticeable development of  a secondary breast tumor.
A 59-year-old female visited our hospital in August 2017, 
complaining of  breast mass. Upon presentation at our 
hospital, the palpable left-breast mass was subjected to 
imaging examinations. Ultrasonography revealed the mass to 
be an irregular, ill-defined and hypoechoic tumor (BI-RADS 
5), measuring 19 mm × 15 mm (Figure 1A). X-ray showed the 
mass to be 16.7 mm × 19.4 mm (Figure 1B). MRI displayed 
a single enhancing lesion in left breast (Figure 1D and E). A 
tumor sample was obtained by rough needle puncture, and 
subsequent immunohistochemistry (IHC) staining indicated 
invasive breast cancer with signet ring cell carcinoma (Figure 
1C). Immunotyping showed negativity for breast cancer 
markers like estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor receptor-2 (Her-2) 
but positivity for rectal cancer markers such as cytokeratin 
(CK)7, CK20, villin, CDH17 and CDX-2; Ki-67 detection 
showed a 20% positive rate. 
Past medical history showed that the patient had a 2-months 
history of  recurrent diarrhea and anal dilatation in April of  
2016. Routine blood investigations showed results in the 
normal ranges. Abdominal contrast-enhanced computed 
tomography (CT) showed a mass in the rectum that 
was accompanied by hyperplastic lymph nodes (Figure 
2A). Pathology assessment of  a biopsy sample obtained 
via colonoscopy provided the diagnosis of  mucous 
adenocarcinoma and signet ring cell carcinoma (images 
unavailable). Further evaluation by magnetic resonance 
imaging revealed the tumor to be in the rectum, ~ 5.1 cm 
diameter in size and ~ 5.5 cm from the anus and encircling 
the intestinal cavity and a swollen lymph nodes; the findings 
prompted suspicion of  metastasis (Figure 2B). Following 
multidisciplinary care team discussion, the patient was started 
on a neoadjuvant radiotherapy and chemotherapy. From June 
30, 2016 to August 4, 2016, the patient received 50 Gy/25F 
radiation (2 Gy each visit, Monday to Friday for 5 weeks) 
and 7-days rounds of  1500 mg Xeloda® (Roche, Shanghai, 
China) twice daily from day 1 to day 5 with rest on day 6 and 
day 7. On August 30, 2016, the neoadjuvant chemotherapy 
was changed to a 14-days regimen of  400 mg oxaliplatin 
(Hengrui, Jiangsu, China) on day 1 and 1500 mg Xeloda® 
twice daily from day 1 to day 14 (Figure 2C). On October 
14, 2016, the patient underwent abdominoperineal resection 
(Miles’ procedure) and the subsequent pathology assessment 
provided the diagnosis of  mucinous adenocarcinoma 
(pT3N1M0; Figure 2F). The chemotherapeutic regimen was 
changed to an 8-cycles program with once every 14 days of  
200 mg oxaliplatin on day 1 and 1500 mg Xeloda® twice daily 
from day 1 to day 14, and the last time of  chemotherapy is 
March of  2017. The cancer appeared to be resolved (Figure 
2D and E).       
Taking into account the breast metastasis originating from a 
primary rectal cancer, the following chemotherapy regimen 
was ordered: 6-round, 3-days course of  300 mg irinotecan 
(Qilu Pharmaceutical, Hainan, China) on day 1, 4.5 mg 
raltitrexed (Zhengda Tianqin Pharmaceutical Co., Nanjing, 
China) on day 2, and 450 mg bevacizumab (Roche, Shanghai, 
China) on day 3. On May 10, 2018, the patient underwent 
enlarged resection of  the left-breast tumor (pathology-
verified clear margins). The pathology assessment showed 
mucinous adenocarcinoma and IHC evaluation showed 
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Figure 1 Imaging findings and pathological characteristics of the patient’s breast metastasis. A: Ultrasonography revealed a mass 
in the left breast; B: X-ray of the left breast; C: Pathology (hematoxylin and eosin) of the rough needle puncture of the tumor; D: 
Axial magnetic resonance imaging (MRI) of the breasts; E: Coronal MRI of the left breast; F: Pathology (hematoxylin and eosin) 
of the resected tumor.
Figure 2 Imaging findings and pathological characteristics of the patient’s previous rectal carcinoma. A: Computed tomography 
(CT) showed a mass in the rectum (thick red arrow), accompanied by hyperplastic lymph nodes (thin red arrow); B: Magnetic 
resonance imaging (MRI) also showed the rectal cancer (red arrows); C: CT image made after the adjuvant chemotherapy and 
radiotherapy, showing regression of the tumor (red arrow); D and E: CT and MRI images, respectively, made after the Miles’ 
surgical procedure; F: Pathology (hematoxylin and eosin) showed mucinous adenocarcinoma.
Figure 3 Timeline of multimodal treatments.
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positivity for CK20, CDH17, SATB2, CDX-2 and Ki-67 but 
negativity for ER, PR, and Her-2 (Figure 1F and Figure 3). 
After breast surgery, the patient was admitted to the Oncology 
Department for postoperative chemotherapy. Follow-up 
examinations have been performed every 6 months, with no 
evidence of  recurrence or novel distant metastasis up to the 
most recent 2-year follow-up.
Discussion
Colorectal cancer is the third most common cancer in 
humans and the second leading cause of  mortality due to 
distant metastasis[1]. The most common areas of  metastasis 
from rectal cancer are liver, lung and brain[1]. Breast metastasis 
from rectal cancer cases are extremely rare in clinical 
practice, with only 10 such patients having been described in 
the literature[2-7]. We reason that secondary breast metastasis 
may be a special type of  rectal cancer, with a metastatic 
pathway involving blood or an axillary vein. The first step in 
diagnosis is to definitively identify whether the breast mass 
is a primary tumor or metastasis; this can be accomplished 
by combining the results of  pathology and IHC. ER, PR and 
Her-2 are biomarkers for breast cancer, and CK20, CDH17, 
SATB2 and CDX-2 are biomarkers for rectal cancer[8, 9]. 
Additionally, some other suspected immunohistochemical 
makers depended on what cancer is suspected. Moreover, it is 
important to identify any case of  “triple-negative” (ER-, PR-, 
Her-2-) breast cancer according to the previous malignancy 
and history, as such requires specialized treatment.
At present, the pathogenic mechanism of  rectal cancer 
metastasizing to the breast remains unclear. Rectal cancer-
originating metastatic disease in the breast, itself, is a marker 
for disseminated metastatic spread and indicates a poor 
prognosis. For these patients, we suggest performing a general 
imaging examination (e.g., positron emission tomography-
CT) to evaluate the general state and monitor the response to 
treatment. Recently, gene sequencing for cancers has become 
a hot topic of  investigation, with some studies showing 
benefit to the patients, such as effectiveness in detecting 
curative effects of  targeted medicine[10]. Furthermore, 
radiofrequency ablation (commonly referred to as RFA) is 
an established procedure for treatment of  various advanced 
cancers[11, 12]. A systematic review showed RFA to be feasible 
and safe with only minor related complications in breast 
cancer patients[13]. For our patient, if  the breast metastasis 
recurs, we may consider RFA as one of  the potent treatment. 
Herein, we report a rare case of  breast metastasis from 
rectal carcinoma (Figure 3). The diagnosis was established 
by good history of  precious malignancy, histopathology 
and IHC findings. Reporting of  this case may help in the 
development of  personalized medicine, targeted therapy, 
and immunotherapy approaches that will provide effective 
strategies to better manage future patients with this rare 
disease entity. 
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